These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36872620)

  • 1. Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer.
    Regnery S; Franke H; Held T; Trinh T; Naveh A; Abraham Y; Hörner-Rieber J; Hess J; Huber PE; Debus J; Lopez Perez R; Adeberg S
    Head Neck; 2023 Apr; 45(4):838-848. PubMed ID: 36872620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
    Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
    Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
    Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
    Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    Gebre-Medhin M; Brun E; Engström P; Haugen Cange H; Hammarstedt-Nordenvall L; Reizenstein J; Nyman J; Abel E; Friesland S; Sjödin H; Carlsson H; Söderkvist K; Thomasson M; Zackrisson B; Nilsson P
    J Clin Oncol; 2021 Jan; 39(1):38-47. PubMed ID: 33052757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
    Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
    Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
    Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
    Ang MK; Montoya JE; Tharavichitkul E; Lim C; Tan T; Wang LY; Wee J; Soong YL; Fong KW; Ng QS; Tan DS; Toh CK; Tan EH; Lim WT
    Head Neck; 2021 May; 43(5):1641-1651. PubMed ID: 33547683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells.
    Schneider S; Thurnher D; Kadletz L; Seemann R; Brunner M; Kotowski U; Schmid R; Lill C; Heiduschka G
    Oral Dis; 2016 Nov; 22(8):797-804. PubMed ID: 27476950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
    Xiang M; Colevas AD; Holsinger FC; Le QX; Beadle BM
    J Natl Compr Canc Netw; 2019 Sep; 17(9):1065-1073. PubMed ID: 31487677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.
    Breheret M; Lubgan D; Haderlein M; Hecht M; Traxdorf M; Schmidt D; Müller S; Kitzsteiner C; Kuwert T; Iro H; Fietkau R; Semrau S
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):245-254. PubMed ID: 31583430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
    Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
    Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.